Asahi deal not enough to save RaQualia from wider losses
This article was originally published in Scrip
Executive Summary
The pharma division of the diversified Japanese chemicals and materials group Asahi Kasei has signed a collaborative research agreement with RaQualia Pharma aimed at the discovery of new therapeutics against a specific (but unidentified) ion channel target.